Hepatocellular carcinoma (HCC) is the most prevalent form of liver cancer ... The role of systemic therapies in the ...

During a Community Case Forum event, Stacey Stein, MD, discussed data guiding the use of current regimens for the treatment ...

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, with over 70% of patients diagnosed at ...

Dr. Corey: The patient was referred to this hospital for management of hepatocellular carcinoma complicating MASH cirrhosis. Management options for hepatocellular carcinoma include locoregional ...

Tempest Therapeutics is hunkering down to weather the storm that has engulfed its operations. | Tempest Therapeutics is ...

Advanced hepatocellular carcinoma (HCC) with pulmonary metastasis (PM) has a poor prognosis, and optimal treatment strategies remain controversial. This study compared pulmonary metastasectomy and ...

As India marks World Liver Day, health experts are raising concerns over the rising burden of liver cancer, a disease often ...

The following is a summary of "Epigenetic-modification associated hnRNPA3 acts as a prognostic biomarker and promotes malignant progression of HCC," published in the April 2025 issue of BMC Cancer by ...

The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and ...